Abstract:Precision medicine relies on the idea that, for a particular targeted agent, only a subpopulation of patients is sensitive to it and thus may benefit from it therapeutically. In practice, it is often assumed based on preclinical data that a treatment-sensitive subpopulation is known, and moreover that the agent is substantively efficacious in that subpopulation. Due to important differences between preclinical settings and human biology, however, data from patients treated with a new targeted agent often show that one or both of these assumptions are false. This paper provides a Bayesian randomized group sequential enrichment design that compares an experimental treatment to a control based on survival time and uses early response as an ancillary outcome to assist with adaptive variable selection and enrichment. Initially, the design enrolls patients under broad eligibility criteria. At each interim decision, submodels for regression of response and survival time on a baseline covariate vector and treatment are fit; variable selection is used to identify a covariate subvector that characterizes treatment-sensitive patients and determines a personalized benefit index, and comparative superiority and futility decisions are made. Enrollment of each cohort is restricted to the most recent adaptively identified treatment-sensitive patients. Group sequential decision cutoffs are calibrated to control overall type I error and account for the adaptive enrollment restriction. The design provides a basis for precision medicine by identifying a treatment-sensitive subpopulation, if it exists, and determining whether the experimental treatment is superior to the control in that subpopulation. A simulation study shows that the proposed design reliably identifies a sensitive subpopulation, yields much higher generalized power compared to several existing enrichment designs and a conventional all-comers group sequential design, and is robust.

Repeated Significance Tests of Linear Combinations of Sensitivity and Specificity of a Diagnostic Biomarker

Hybrid Design Evaluating New Biomarkers when There is an Existing Screening Test

Nonparametric Sample Size Estimation for Sensitivity and Specificity with Multiple Observations per Subject

Statistical inference for diagnostic test accuracy studies with multiple comparisons

A Dunnett-Type Test and Its Sample Size Calculation for Comparing K ROC Curves with a Control

Two-Stage Marker-Stratified Clinical Trial Design in the Presence of Biomarker Misclassification

Optimal Marker-Strategy Clinical Trial Design to Detect Predictive Markers for Targeted Therapy

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

A Sequential Significance Test for Treatment by Covariate Interactions

A novel method to guide biomarker combinations to optimize the sensitivity

A multiple testing framework for diagnostic accuracy studies with co-primary endpoints

Comparison of Diagnostic Markers with Repeated Measurements: a Non-Parametric ROC Curve Approach.

Combining Biomarkers to Improve Diagnostic Accuracy in Detecting Diseases With Group‐Tested Data

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

Prediagnostic evaluation of multicancer detection tests: Design and analysis considerations

Statistical Methods for Selective Biomarker Testing

On the Optimal Combination of Elliptically Distributed Biomarkers to Improve Diagnostic Accuracy

Two-Stage Adaptive Enrichment Designs with Survival Outcomes and Adjustment for Misclassification in Predictive Biomarkers

Two‐stage stratified designs with survival outcomes and adjustment for misclassification in predictive biomarkers

Sample size estimation in diagnostic test studies of biomedical informatics

Medical diagnostic accuracy measures: an innovative approach based on the area under predictive values curves